383 related articles for article (PubMed ID: 29617652)
41. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
[TBL] [Abstract][Full Text] [Related]
42. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
43. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
44. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
[TBL] [Abstract][Full Text] [Related]
45. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
46. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Petrelli A; Rizzolio S; Pietrantonio F; Bellomo SE; Benelli M; De Cecco L; Romagnoli D; Berrino E; Orrù C; Ribisi S; Moya-Rull D; Migliore C; Conticelli D; Maina IM; Puliga E; Serra V; Pellegrino B; Llop-Guevara A; Musolino A; Siena S; Sartore-Bianchi A; Prisciandaro M; Morano F; Antista M; Fumagalli U; De Manzoni G; Degiuli M; Baiocchi GL; Amisano MF; Ferrero A; Marchiò C; Corso S; Giordano S
Cancer Res; 2023 May; 83(10):1699-1710. PubMed ID: 37129948
[TBL] [Abstract][Full Text] [Related]
47. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
48. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
49. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
51. PARP Inhibitors for Cancer Therapy.
Lin KY; Kraus WL
Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
[TBL] [Abstract][Full Text] [Related]
52. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
53. Secondary Somatic Mutations Restoring
Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O'Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL;
Cancer Discov; 2017 Sep; 7(9):984-998. PubMed ID: 28588062
[TBL] [Abstract][Full Text] [Related]
54. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
55. A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Pettitt SJ; Shao N; Zatreanu D; Frankum J; Bajrami I; Brough R; Krastev DB; Roumeliotis TI; Choudhary JS; Lorenz S; Rust A; de Bono JS; Yap TA; Tutt ANJ; Lord CJ
Oncogene; 2023 Sep; 42(36):2701-2709. PubMed ID: 37491606
[TBL] [Abstract][Full Text] [Related]
56. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
57. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of
Biegała Ł; Kołat D; Gajek A; Płuciennik E; Marczak A; Śliwińska A; Mikula M; Rogalska A
Cells; 2024 May; 13(10):. PubMed ID: 38786089
[TBL] [Abstract][Full Text] [Related]
58. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
59. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
Pennington KP; Wickramanayake A; Norquist BM; Pennil CC; Garcia RL; Agnew KJ; Taniguchi T; Welcsh P; Swisher EM
Gynecol Oncol; 2013 Mar; 128(3):493-9. PubMed ID: 23246380
[TBL] [Abstract][Full Text] [Related]
60. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
